What’s the future of AI in transforming drug discovery?—with Mika Newton

Mika Newton and Tom Neyarapally explore how advancements in AI are accelerating the development of new algorithms, improving target discovery, and enhancing high-throughput screening. The conversation highlights the challenges and opportunities in aggregating innovative technologies, the convergence of AI tools in healthcare, and the potential for personalized and economically viable drug development. - - - For a summary and key takeaways, visit: https://xcures.com/ai-and-healthcare/... - - -Timestamps - - - - 00:00 The Future of AI 01:39 Convergence of Technologies 03:39 Challenges in AI Drug Discovery 08:37 Optimizing Drug Development 12:21 The Need for Better Data Access - - - #aiandhealthcare #drugdiscovery #aihealthcare 🔴Like, Subscribe, and Share to see more of this type of content! — ABOUT AI AND HEALTHCARE — AI and Healthcare—with Mika Newton and Dr. Sanjay Juneja is an engaging interview series featuring world-renowned leaders shaping the intersection of artificial intelligence and medicine. Discover how AI is transforming healthcare today, addressing real-world challenges and improving patient outcomes. This series caters to anyone's listening style with bite-sized, commute-friendly insights and full-length interviews. Join co-hosts Mika Newton, CEO of xCures, and Dr. Sanjay Juneja, a globally recognized oncologist and AI thought leader at Tempus AI, as they explore cutting-edge innovations with industry pioneers. — ABOUT TOM NEYARAPALLY — Tom Neyarapally is the CEO and Co-Founder of Archetype Therapeutics, an AI-native company pioneering the use of generative chemogenomics in patient data-driven drug discovery and repurposing in cancer and other diseases. The Archetype platform enables virtual phenotypic screening of billions of molecules per day for their effect on clinical outcomes in cohorts of patients with unmet medical need. Previously Tom was CCO and founding team member at Sema4, a patient-centered health intelligence and genetic testing company. He was also a member of the founding team and Executive Vice President, Corporate Development at the causal AI drug discovery company Aitia. After graduate school, Tom served as a corporate and IP lawyer at Chadbourne Parke LLP and Frommer Lawrence Haug LLP. He started his career after his undergraduate chemical engineering studies as an analyst focused on pharmaceuticals at the management consulting firm Arthur D. Little. — ABOUT MIKA NEWTON — With over 25 years of leadership experience in life sciences, Mika Newton is the CEO of xCures, a health technology company that has created an AI-enabled, medical records data structuring platform. Mika is an expert in healthcare data management, with a focus on data completeness and universality. Mika is on the editorial board of AI in Precision Oncology and has a proven track record of bringing transformative technologies to market and fostering innovation.   / mikanewton   Additional listening channels, at xcures.com/ai-and-healthcare Views expressed by Mr Newton and guests are solely their own and are not attributable to xCures, Tempus, or any of our guests' affiliations.